李淑晶

个人信息Personal Information

副教授

硕士生导师

性别:女

毕业院校:大连理工大学

学位:博士

所在单位:生物工程学院

办公地点:生物楼416

电子邮箱:lsj@dlut.edu.cn

扫描关注

论文成果

当前位置: 中文主页 >> 科学研究 >> 论文成果

Checkpoint suppressor 1 suppresses transcriptional activity of ERalpha and breast cancer cell proliferation via deacetylase SIRT1.

点击次数:

论文类型:期刊论文

发表时间:2018-01-01

发表刊物:Cell death & disease

收录刊物:PubMed、SCIE

卷号:9

期号:5

页面范围:559

ISSN号:2041-4889

摘要:Breast cancer is a highly heterogeneous carcinoma in women worldwide, but the underlying mechanisms that account for breast cancer initiation and development have not been fully established. Mounting evidence indicates that Checkpoint suppressor 1 (CHES1) is tightly associated with tumorigenesis and prognosis in many types of cancer. However, the definitive function of CHES1 in breast cancer remains to be explored. Here we showed that CHES1 had a physical interaction with estrogen receptor-alpha (ERalpha) and repressed the transactivation of ERalpha in breast cancer cells. Mechanistically, the interaction between CHES1 and ERalpha enhanced the recruitment of nicotinamide adenine dinucleotide (NAD+) deacetylase Sirtuin 1 (SIRT1), and it further induced SIRT1-mediated ERalpha deacetylation and repression on the promoter-binding enrichment of ERalpha. In addition, we also found that the expression of CHES1 was repressed by estrogen-ERalpha signaling and the expression level of CHES1 was significantly downregulated in ERalpha-positive breast cancer. The detailed mechanism was that ERalpha may directly bind to CHES1 potential promoter via recognizing the conserved estrogen response element (ERE) motif in response to estrogen stimulation. Functionally, CHES1 inhibited ERalpha-mediated proliferation and tumorigenesis of breast cancer cells in vivo and in vitro. Totally, these results identified a negative cross-regulatory loop between ERalpha and CHES1 that was required for growth of breast cancer cells, it might uncover novel insight into molecular mechanism of CHES1 involved in breast cancer and provide new avenues for molecular-targeted therapy in hormone-regulated breast cancer.